ETV6 antibody
- Known as:
- ETV6 (anti-)
- Catalog number:
- orb39610
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ETV6 antibody
Related genes to: ETV6 antibody
- Gene:
- ETV6 NIH gene
- Name:
- ETS variant 6
- Previous symbol:
- -
- Synonyms:
- TEL
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-28
- Date modifiied:
- 2019-04-23
Related products to: ETV6 antibody
Related articles to: ETV6 antibody
- Acute lymphoblastic leukemia (ALL) is a common pediatric malignancy and shows marked genetic heterogeneity. Transcriptomic profiling may improve molecular diagnosis and risk stratification, particularly in admixed Latin American populations. - Source: PubMed
Publication date: 2026/09/23
Perez-Arismendi EdwardGomez-Lopera NataliaVillada Juan CamiloMoreno-Garcia DianaArroyave-Ossa FedericoQuiroz Lina MariaValencia-Zuluaga NataliaMunoz-Martinez JavierRestrepo-Rincon AlexandraGarces-Arias AndresVasquez-Palacio Gonzalo - The molecular interpretation of eosinophilic neoplasms harboring t(5;12) may be challenging because cytogenetic breakpoint assignments can suggest a PDGFRB rearrangement without identifying the underlying fusion. We retrospectively investigated a woman with a chronic eosinophilic myeloid neoplasm initially investigated in 2002, in whom a subsequent t(5;12)(q31 ~ q33;p13) raised suspicion of PDGFRB involvement. Contemporary molecular investigations failed to identify the rearrangement, and an empiric trial of imatinib produced no meaningful hematologic response. Seventeen years later, blast transformation was accompanied by persistence of t(5;12) and acquisition of del(9)(q22). Fluorescence in situ hybridization demonstrated ETV6 rearrangement but no PDGFRB break-apart pattern, indicating en bloc translocation of the PDGFRB locus. Targeted RNA sequencing of archived RNA extracted from cryopreserved peripheral blood cells collected in 2004 subsequently identified a strong-evidence ETV6::ACSL6 fusion joining exon 2 of ETV6 to exon 2 of ACSL6, supported by 1847 reads and 218 unique start sites. Targeted myeloid DNA sequencing detected no mutation within the regions analyzed. Identification of ETV6::ACSL6 shifted the biological interpretation away from presumed constitutive tyrosine kinase activation toward a proposed cytokine regulatory rewiring involving the 5q31 cytokine locus, consistent with published experimental evidence and the absence of response to imatinib. This case illustrates how contemporary RNA-based fusion detection can resolve a historically uncharacterized structural rearrangement and refine biological interpretation and therapeutic expectations, while documenting an unusually prolonged natural history of an ETV6::ACSL6-associated eosinophilic myeloid neoplasm. - Source: PubMed
Lambert FrédéricCarazo Rafael FernandezKoopmansch BenjaminDardenne ElisaSidon PierreVertenoeil GaëlleHeimann Pierre - Secretory carcinoma (SC) is a rare, low-grade malignant neoplasm of the salivary glands, most commonly arising in the parotid gland. Involvement of the minor salivary glands of the buccal mucosa is exceedingly rare, with only a handful of cases reported in the literature. A 30-year-old female presented with a one-year history of a swelling over the left cheek. On clinical examination, a 2 × 2 cm, lobulated, cystic swelling was identified in the left buccal mucosa. Fine-needle aspiration of the swelling showed predominantly eosinophilic material with occasional scattered cells. The lesion was surgically excised and submitted for histopathological examination. Gross examination revealed a gray-brown, soft-tissue mass measuring 2.5 × 2 × 1 cm. On serial sectioning, a well-circumscribed cystic, gray-white lesion measuring 1 cm in diameter was identified. Histopathological examination of the lesion showed features consistent with SC. The tumor cells were positive for GATA3, mammaglobin, S100, and CK7. The postoperative positron emission tomography-computed tomography revealed no tumor deposit, and the patient remained free of local recurrence during the six-month follow-up period. - Source: PubMed
Publication date: 2026/09/02
Hasan ZoyaSingh MeetaKaur KiratMeher Ravi - The fusion is a recurrent oncogenic alteration in sporadic pediatric papillary thyroid carcinoma (PTC), frequently associated with multifocal disease and pulmonary metastasis. However, the molecular and cellular consequences of expression in thyroid follicular cells remain poorly defined. Here, we investigated the biological effects of in PCCL3 thyroid cells and compared them with those induced by clinically established pediatric PTC oncogenic drivers, including , , , , and wild-type . -expressing cells exhibited the most robust MAPK/ERK activation, characterized by markedly enhanced ERK and MEK phosphorylation relative to all other oncogenic drivers analyzed. By contrast, STAT3 and AKT signaling remained comparatively modest and did not show consistent oncogene-specific activation patterns. Functionally, expression induced features of thyroid dedifferentiation, including reduced sodium-iodide symporter (NIS) expression and impaired iodide uptake. Concomitantly, -expressing cells exhibited increased frequencies of micronuclei and chromatin bridges, together with disruption of three-dimensional telomere architecture, including reduced telomere signal number and intensity, altered spatial organization, and increased nuclear volume. Three-dimensional structured illumination microscopy (3D-SIM) further demonstrated chromatin remodeling, characterized by increased chromatin condensation accompanied by enlarged interchromatin spaces. Collectively, these findings suggest that is a dominant oncogenic driver of sustained MAPK/ERK signaling coupled to thyroid dedifferentiation, nuclear architectural remodeling, telomere dysfunction, and genomic instability. These coordinated molecular and structural alterations provide a mechanistic basis for the aggressive clinical course observed in -driven pediatric PTC. - Source: PubMed
Publication date: 2026/09/18
Sisdelli LuizaRocha Welbert GomesDias Thomaz Débora MotaHatanaka RoxaneCosta da Silva Renata ElenHenrique GuilhermeSerrano-Nascimento CarolineFabião MatheusRangel-Pozzo AlineMai SabineCerutti Janete Maria - Mammary analog secretory carcinoma (MASC) is a rare malignant tumor of the salivary glands that exhibits significant morphological, immunohistochemical, and molecular similarities with secretory carcinoma of the breast, including the characteristic - gene fusion. The diagnosis of this condition remains challenging due to its histopathologic overlap with other low-grade salivary gland tumors, such as acinic cell carcinoma and mucoepidermoid carcinoma. The following report details two cases of MASC manifesting in the right parotid gland of a 37-year-old male and a 23-year-old female. Both subjects exhibited slow-growing, painless swellings and radiologic findings indicative of benign lesions. The surgical excision procedure was performed on the first patient via extracapsular dissection, while the second patient underwent superficial parotidectomy. Both procedures were carried out under the supervision of intraoperative facial nerve monitoring. A subsequent histopathological and immunohistochemical examination revealed a glandulocystic growth pattern with eosinophilic secretions and strong immunoreactivity for CK7, S100, and mammaglobin. Although molecular testing for the - fusion was not performed, the clinical, morphological, and immunophenotypic findings supported the diagnosis of low-grade secretory carcinoma. The patients exhibited uncomplicated recovery, with transient facial nerve paresis in the second patient resolving within 3 months. The first patient remains disease-free after 40 months of clinical and radiological follow-up, while the second patient has shown no evidence of recurrence after 21 months of follow-up. The cases under consideration serve to emphasize the importance of integrating morphology and immunohistochemistry in routine practice, with molecular confirmation remaining the diagnostic gold standard whenever it is available. It is imperative to be aware of this entity to ensure an accurate diagnosis, optimal surgical management, and appropriate long-term surveillance. Emerging evidence suggests that targeted therapy with NTRK inhibitors may represent a promising option for advanced or recurrent disease. - Source: PubMed
Publication date: 2026/09/26
Ferragina FrancescoBarca IdaTarallo GiuseppeSottile Angelo RIoppolo Maria GraziaCristofaro Maria Giulia